Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
 
Survey
We asked 60 industry leaders, Which of the following has the most negative impact
on biopharmaceutical drug development?

M&As 55%

Counterfeit drugs

18%
Regulations 27%
 

Talk to us:
jupton@advanstar.com

Advertise with us:
wblow@advanstar.com

5 Aug, 2014
US and France Establish Partnership Payout for the Best in Start-Up Innovations
The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports. Read more
What Can We Expect from the European Parliament’s New Term?
Europe departs for its annual holiday— sacrosanct, even amid the continuing economic woes, the multiple crises in the Middle East, and the dark mysteries of Russia’s intentions in its former satellites — the question remains unresolved as to what to expect from the new European Parliament in the new term. Philip Ward considers the options... Read more
EMA Invites Comments on Consultation for Flu Vaccine Development
The European Medicines Agency (EMA) has released the second module of a new overarching guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate their prompt assessment ... Read more
Where’s the Wearable Technology Revolution in Healthcare?
Apple’s iWatch may be yet to happen, but Peter Houston is reassured that the development of wearable devices in the pharma space is progressing nicely.... Read more
Only Fools Rush In: The Importance of Pre-Acquisition Due Diligence
One reason why compliance should have a seat at the M&A table early on is so that a company’s compliance and legal teams stay informed of upcoming deals in the pipeline in order to marshal the necessary resources prior to the announcement of a takeover bid, writes Severin Wirz.... Read more
Also in this issue
Big Data in R&D
Pharm Exec 2014 Dealmakers Outlook
Pharm Exec eBooks Available as Apps